LifeStrands Genomics

What LifeStrands Genomics does

LifeStrands Genomics is a Singapore-headquartered clinical genomics laboratory and a wholly-owned subsidiary of Pathology Asia Holdings (PAH). Founded in 2021 and operating with 11-50 employees, the company offers a comprehensive menu of physician-ordered genetic tests spanning four clinical domains: hereditary condition screening (including Ambry Genetics panels such as BRCANext, CancerNext, CardioNext, FHNext, and ExomeNext), precision oncology tumor profiling (OncoStrands across multiple tiers), reproductive health via non-invasive prenatal testing (The Vantage Test using whole genome sequencing), and pharmacogenomics (CYP2C19 genotyping and a 15-gene PGx Comprehensive panel delivered with BasePair Genomics). Supporting offerings include spatial biology/translational research and WES/WGS sequencing services. The company is embedded in Singapore's National Precision Medicine programme through a partnership with PRECISE (RIE 2025 HHP, Phase II CIPs), giving it formal alignment with national genomic initiatives.

The underlying technology stack combines short-read and long-read sequencing platforms (Illumina, PacBio, Oxford Nanopore as listed programme partners) with proprietary assay design including RNAInsight for enhanced variant detection in hereditary panels. Tests are processed at an accredited clinical laboratory with reported turnaround times of 4-7 working days, and specimens are accepted via a clinical ordering portal (Ovation) and direct healthcare provider engagement. The platform integrates third-party branded test content (Ambry, BasePair) alongside own-branded Vantage and OncoStrands offerings, enabling a full-spectrum hereditary-to-pharmacogenomics menu without internal development of every assay.

LifeStrands operates a service-based B2B revenue model, billing for clinical genetic testing services delivered to healthcare providers, clinical laboratories, academic institutions, and pharmaceutical/biotech clients. Go-to-market is sales-led via regional field sales targeting HCPs, laboratories, and institutional partners, supplemented by content marketing, professional events (e.g., FPH ASM at Farrer Park Hospital), and a dedicated clinical portal. Pricing is not publicly disclosed. Geographic focus is Singapore and Southeast Asia, with no external funding disclosed — operations are funded internally within the Pathology Asia Holdings corporate group.

Name

LifeStrands Genomics

Legal name

LifeStrands Genomics Pte. Ltd

Website

https://lifestrandsgx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

LifeStrands Genomics is a Singapore-headquartered clinical genomics laboratory, subsidiary of Pathology Asia Holdings, providing hereditary cancer screening, NIPT, oncology profiling, and pharmacogenomics testing to healthcare providers and clinical laboratories across Southeast Asia.

Ownership category

akta.pro rank

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Clinical Genetic Testing Services: Revenue generated from providing clinical genetic testing services including Non-Invasive Prenatal Testing (Vantage Test), hereditary cancer screening (Ambry Genetics tests including BRCANext, CancerNext, CardioNext, FHNext, ExomeNext), precision oncology (OncoStrands tumor profiling), and pharmacogenomics (CYP2C19 and PGx Comprehensive). Services are offered to healthcare providers and clinical laboratories with turnaround times of 4-7 working days.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

LifeStrands Genomics is a clinical genomics laboratory providing genetic testing services to healthcare providers across hereditary conditions (Ambry Genetics panels including BRCANext, CancerNext, FHNext, CardioNext, ExomeNext), reproductive health (The Vantage® NIPT using whole genome sequencing), precision oncology (OncoStrands® tumor profiling), and pharmacogenomics (CYP2C19 genotyping and PGx Comprehensive 15-gene panel). The company operates from Singapore and distributes tests through clinics, hospitals, and clinical laboratories with 4-7 working day turnaround times.

Product overview

LifeStrands Genomics is a clinical genomics laboratory offering a comprehensive portfolio of genetic testing services. The core clinical tests include Hereditary (hereditary cancer and genetic condition testing), Precision Oncology (tumor profiling and cancer treatment selection), Reproductive (Non-Invasive Prenatal Testing via The Vantage® Test), and Pharmacogenomics (medication response testing via CYP2C19 and PGx Comprehensive). Supporting services include Spatial Biology for translational research, Sequencing Services (WES/WGS), and laboratory capabilities such as Wet Lab Services, Interpretation Services, and Bioinformatics. The company distributes third-party branded tests including Ambry® Genetics hereditary panels (BRCANext, CancerNext, RNAInsight, FHNext, CardioNext, ExomeNext) and OncoStrands® tumor profiling.

Differentiator

Problem solved

Functional benefit

Brands

• The Vantage® Test: Non-Invasive Prenatal Screening Test (NIPT/NIPS) using whole genome sequencing to estimate risk of chromosomal abnormalities
• OncoStrands®
• BasePair Genomics

Products and services

• Hereditary Testing Clinical genetic testing services for hereditary conditions, ranging from selected to comprehensive screening to find diagnoses or understand whether conditions are inherited. Includes Ambry Genetics panels distributed through LifeStrands.
• Precision Oncology Oncology testing services for patient management through understanding genes responsible for cancer to find the most effective and actionable treatments available. Includes OncoStrands® tumor profiling with multiple tiers.
• Reproductive Testing Non-Invasive Prenatal Testing (NIPT) services providing genetic insights that uncover the baby's risk of certain abnormalities to guide important health decisions during pregnancy. Includes The Vantage® Test.
• The Vantage® Test Non-Invasive Prenatal Screening Test (NIPT/NIPS) using whole genome sequencing technology to estimate the risk of chromosomal abnormalities and genetic conditions such as Down's Syndrome in a developing fetus.
• Pharmacogenomics Testing Pharmacogenomics testing services to assist medication decisions by providing evidence-based, genetically guided medication alerts based on patient genetics. Includes CYP2C19 Genotyping and PGx Comprehensive.
• PGx Comprehensive by Basepair Genomics Complete pharmacogenomics clinical support tool analyzing fifteen genes covering liver metabolism, drug transporters and receptors to assist medication selection for various conditions.
• CYP2C19 Genotyping CYP2C19 genotyping screening assay that tests for variants associated with altered drug metabolism, particularly for clopidogrel, to guide drug selection and dosage adjustments.
• OncoStrands® Tumour Profiling Tumor profiling service with multiple tiers (Essential, Extended, Comprehensive, Comprehensive + HRD, HRD, Comprehensive Fusion) for cancer diagnosis and treatment selection.
• Hereditary Tests by Ambry® Genetics Hereditary cancer and genetic testing panels offered through Ambry Genetics including BRCANext, CancerNext, RNAInsight, FHNext, CardioNext, and ExomeNext tests.
• Spatial Biology Services Translational genomics service with multi-omics research and clinical approach that leads to new discoveries in spatial biology.
• Sequencing Services (WES/WGS) Sequencing services including Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) for research and clinical applications.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Precision Health Research Singapore (PRECISE)coreStrategic or Co-development PartnerLifeStrands is collaborating with Singapore PRECISE as part of Singapore RIE 2025 HHP goals for Clinical Implementation Projects (CIPs) in Phase II. The partnership focuses on offering genetic testing within LifeStrands laboratory to drive adoption and improve patient outcomes to fellow Singaporeans. This aligns with Singapore's National Precision Medicine programme led by PRECISE.
• IlluminasupportingTechnology or IntegrationIllumina is listed as a genomics partner in the Singapore National Precision Medicine programme coordinated by PRECISE. Illumina provides sequencing technology and platforms for genomic research initiatives.
• Oxford Nanopore TechnologiessupportingTechnology or IntegrationOxford Nanopore Technologies is listed as a genomics partner in the Singapore National Precision Medicine programme coordinated by PRECISE. The company provides nanopore sequencing technology for genomic analysis.
• PacBio (Pacific Biosciences)supportingTechnology or IntegrationPacBio is listed as a genomics partner in the Singapore National Precision Medicine programme coordinated by PRECISE. PacBio provides long-read sequencing technology for genomic research applications.
• Ambry GeneticscoreTechnology or IntegrationLifeStrands offers hereditary tests developed by Ambry Genetics including BRCANext, CancerNext, CardioNext, FHNext, ExomeNext, and RNAInsight. These are comprehensive genetic testing panels for hereditary cancer, cardiovascular conditions, and rare diseases.
• BasePair GenomicscoreTechnology or IntegrationLifeStrands offers pharmacogenomics tests (CYP2C19 genotyping and PGx Comprehensive) developed by BasePair Genomics. These tests analyze drug metabolism genes to guide medication selection and dosing.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Customer concentration

• YouTubeyoutube.com/channel/UCBqHs_Ehi0U0EYf-kHAxELA
• Facebookfacebook.com/Lifestrandsgx
• LinkedInlinkedin.com/company/lifestrandsgx

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeStrands Genomics